BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang SF, Chang IC, Hong CC, Yen TC, Chen CL, Wu CC, Tsai CC, Ho MC, Lee WC, Yu HC, Shen YY, Eng HL, Wang J, Tseng HH, Jeng YM, Yeh CT, Chen CL, Chen PJ, Liaw YF. Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol Commun 2018;2:747-59. [PMID: 29881825 DOI: 10.1002/hep4.1182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Yang L, Shao X, Jia S, Zhang Q, Jin Z. Interleukin-35 Dampens CD8+ T Cells Activity in Patients With Non-viral Hepatitis-Related Hepatocellular Carcinoma. Front Immunol 2019;10:1032. [PMID: 31134088 DOI: 10.3389/fimmu.2019.01032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
2 Chang T, Hsu N, Chen S, Hsu I, Lee M, Lu S. Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study. Viruses 2022;14:984. [DOI: 10.3390/v14050984] [Reference Citation Analysis]
3 Wu H, Jeng W, Pan M, Hsieh Y, Lu S, Chen C, Yang H. Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection. JHEP Reports 2022;4:100410. [DOI: 10.1016/j.jhepr.2021.100410] [Reference Citation Analysis]
4 Lin YP, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, Yao CC, Tsai MC. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. Front Oncol 2022;12:816472. [PMID: 35186751 DOI: 10.3389/fonc.2022.816472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Su SY, Lee LT, Lee WC. Mortality trends in chronic liver disease and cirrhosis from 1981 to 2015 in Taiwan. Popul Health Metr 2021;19:36. [PMID: 34600536 DOI: 10.1186/s12963-021-00269-w] [Reference Citation Analysis]
6 Huang YC, Chen YH. Cancer Incidence Characteristic Evolution Based on the National Cancer Registry in Taiwan. J Oncol 2020;2020:1408793. [PMID: 32774368 DOI: 10.1155/2020/1408793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Jeon SK, Lee JM, Joo I, Yoon JH, Lee DH, Lee JY, Han JK. Prospective Evaluation of Hepatic Steatosis Using Ultrasound Attenuation Imaging in Patients with Chronic Liver Disease with Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard. Ultrasound in Medicine & Biology 2019;45:1407-16. [DOI: 10.1016/j.ultrasmedbio.2019.02.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
8 Ho SY, Yuan MH, Chen CC, Liu PH, Hsu CY, Huang YH, Lei HJ, Lee RC, Huo TI. Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. Dig Dis Sci 2020;65:3389-402. [PMID: 31955286 DOI: 10.1007/s10620-020-06053-4] [Reference Citation Analysis]
9 Hu X, Bao M, Huang J, Zhou L, Zheng S. Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Front Oncol 2020;10:541479. [PMID: 33102213 DOI: 10.3389/fonc.2020.541479] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Yang WY, Rao PS, Luo YC, Lin HK, Huang SH, Yang JM, Yuh CH. Omics-based Investigation of Diet-induced Obesity Synergized with HBx, Src, and p53 Mutation Accelerating Hepatocarcinogenesis in Zebrafish Model. Cancers (Basel) 2019;11:E1899. [PMID: 31795276 DOI: 10.3390/cancers11121899] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
11 Chen KY, Huang YH, Teo WH, Chang CW, Chen YS, Yeh YC, Lee CJ, Lo JF. Loss of Tid1/DNAJA3 Co-Chaperone Promotes Progression and Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Novel Model to Stratify Risk of Recurrence. Cancers (Basel) 2021;13:E138. [PMID: 33406664 DOI: 10.3390/cancers13010138] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. Gut Liver 2021;15:451-8. [PMID: 33431715 DOI: 10.5009/gnl20218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Tsai YC, Sou FM, Liu YW, Wu YJ, Yong CC, Chen DW, Huang PY, Cho WR, Chuang CH, Hsiao CC, Hu TH, Tsai MC. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol 2021;21:386. [PMID: 34666694 DOI: 10.1186/s12876-021-01944-w] [Reference Citation Analysis]
14 Tsai F, Liu X, Chen C, Li T, Chiou J, Chuang P, Ko C, Lin T, Liao C, Huang S, Liang W, Lin Y. Chinese herbal medicine therapy and the risk of overall mortality for patients with liver cancer who underwent surgical resection in Taiwan. Complementary Therapies in Medicine 2019;47:102213. [DOI: 10.1016/j.ctim.2019.102213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
15 Lin YH, Lin KH, Yeh CT. Thyroid Hormone in Hepatocellular Carcinoma: Cancer Risk, Growth Regulation, and Anticancer Drug Resistance. Front Med (Lausanne) 2020;7:174. [PMID: 32528965 DOI: 10.3389/fmed.2020.00174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Chen JR, Chao YP, Tsai YW, Chan HJ, Wan YL, Tai DI, Tsui PH. Clinical Value of Information Entropy Compared with Deep Learning for Ultrasound Grading of Hepatic Steatosis. Entropy (Basel) 2020;22:E1006. [PMID: 33286775 DOI: 10.3390/e22091006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Shao YJ, Wu SY. Letter: cohort study examining the association between proton pump inhibitors therapy and risk of hepatocellular carcinoma in Taiwan-authors' reply. Aliment Pharmacol Ther 2018;48:690-1. [PMID: 30132942 DOI: 10.1111/apt.14935] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Shimada S, Kamiyama T, Orimo T, Nagatsu A, Kamachi H, Taketomi A. High HbA1c is a risk factor for complications after hepatectomy and influences for hepatocellular carcinoma without HBV and HCV infection. Hepatobiliary Surg Nutr 2021;10:454-63. [PMID: 34430524 DOI: 10.21037/hbsn.2020.01.03] [Reference Citation Analysis]
19 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
20 Luo L, Li Q, Su Z, Li L, Cai B, Peng Y, Bai Y, Liu F. Genetic Polymorphisms in CD35 Gene Contribute to the Susceptibility and Prognosis of Hepatocellular Carcinoma. Front Oncol 2021;11:700711. [PMID: 34422654 DOI: 10.3389/fonc.2021.700711] [Reference Citation Analysis]